EDAP TMS SA Highlights Advances in HIFU for Endometriosis Care

EDAP TMS SA Showcases Breakthroughs in Endometriosis Treatment

EDAP TMS SA (NASDAQ: EDAP), a pioneer in robotic energy-based therapies, has recently revealed significant advancements in the application of High-Intensity Focused Ultrasound (HIFU) for managing deep infiltrating endometriosis. At the 2024 AAGL Global Congress, held in New Orleans, the company presented compelling clinical data comparing its innovative Focal One HIFU with traditional surgical approaches.

Understanding the Importance of HIFU in Endometriosis Treatment

Focal One HIFU treatment uses robotic technology to target and destroy endometriosis lesions with minimal invasiveness. The presentation featured by Professor Gil Dubernard, a leading gynecologist from France, shed light on the comparative effectiveness of HIFU over surgery. This study focused on patients suffering from deep infiltrating endometriosis—a condition that often requires complex and invasive surgical procedures.

Professor Dubernard noted, “The findings indicate that robotic HIFU could significantly enhance patient recovery by minimizing complications and shortening hospital stays compared to conventional surgery.” This is particularly noteworthy in the context of endometriosis, where treatment options are often limited and invasive.

Study Design and Key Findings

The study encompassed a robust examination of treatment outcomes for 120 patients, divided equally between those undergoing HIFU and those opting for surgical intervention. The retrospective multicenter analysis revealed several crucial insights:

• Patients treated with HIFU exhibited fewer moderate and severe post-operative complications than those who underwent surgery.
• The duration of hospital stay was markedly reduced for patients receiving HIFU therapy.
• Overall, the health improvements noted in HIFU patients were promising, indicating this method as a feasible alternative to aggressive surgical techniques.

These results highlighted the potential of HIFU not just as a treatment option, but as a less invasive solution that could change the standards of care in managing this challenging condition.

Ongoing Research and Future Perspectives

EDAP TMS continues to invest in research, following their ongoing Phase 3 trials aimed at gauging the full effectiveness of Focal One HIFU for deep infiltrating endometriosis. With over 85% of patients from the initial Sham treatment arm opting for HIFU upon symptom recurrence, the data suggests a high interest in this non-invasive technology.

As the healthcare landscape progresses, the company plans to communicate further findings to the FDA as part of their regulatory journey, aiming to solidify the role of robotic HIFU in mainstream gynaecological practices.

About EDAP TMS SA

EDAP TMS SA stands as a significant entity in the global therapeutic ultrasound landscape, advancing minimally invasive medical devices from diagnosis to treatment. The company's commitment to innovation is reflected in the comprehensive range of their Robotic HIFU products, including the notable Focal One device tailored for efficient and effective prostate cancer treatment.

Contact Information

For further inquiries, please reach out to:

Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com

Frequently Asked Questions

What is Focal One HIFU?

Focal One HIFU is a robotic technology used to treat deep infiltrating endometriosis and other medical conditions with minimal invasiveness.

How does HIFU compare to traditional surgery for endometriosis?

Studies indicate that HIFU offers fewer post-operative complications and shorter recovery times compared to traditional surgical methods.

What were the main findings from the 2024 AAGL presentation?

The presentation concluded that HIFU significantly reduces complications and improves patient health outcomes compared to surgical treatments.

What are the future plans for EDAP TMS?

EDAP TMS plans to continue their research and communicate findings to regulatory bodies, enhancing the landscape of endometriosis treatment.

Who can I contact for more information about EDAP TMS?

You can reach out to Blandine Confort or John Fraunces using the provided contact information for inquiries regarding EDAP TMS's therapies.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.